Background: DsbA enzymes assemble bacterial virulence factors and are targets for an entirely new drug class. Results: Proteus mirabilis DsbA was characterized and its structure determined with a peptide bound non-covalently at the active site.
Proteus mirabilis is a significant Gram-negative extra-intestinal human pathogen that belongs to the Enterobacteriaceae family, which also includes other important pathogens such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. Together, the Enterobacteriaceae account for the vast majority of community-acquired and nosocomial urinary tract infections (1, 2) . P. mirabilis is a frequent cause of both complicated and catheter-associated urinary tract infections (3, 4) . Multidrug-resistant strains of clinical pathogenic P. mirabilis have been reported for several decades (1) . For example, clinical isolates of P. mirabilis resistant to streptomycin, tetracycline, kanamycin, chloramphenicol, and polymyxin B were described in the 1960s (5, 6) and since then reports of antibiotic resistance have increased (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
DsbA enzymes from Gram-negative bacteria are targets for the development of anti-virulence drugs that could represent an entirely new class of antimicrobial agents (17, 18) . Drugs that target bacterial virulence could minimize the selective pressure that generates antibiotic resistance and simultaneously preserve the endogenous host microbiome (19) . DsbA is a key target for such drugs because it is essential for the correct folding or assembly of multiple virulence factors, including toxins, fimbrial adhesins, flagella, and type II and type III secretion systems (17) . The mutation of dsbA results in the attenuation of virulence factor production in multiple pathogens (17) , some examples, include P. mirabilis (20) , uropathogenic E. coli (21) , and Burkholderia pseudomallei (21, 22) , Vibrio cholerae (23) , Shigella flexneri (24) , and Salmonella enterica serovar Typhimurium (25) .
DsbA enzymes are thioredoxin-fold proteins (26) localized to the periplasm of Gram-negative bacteria where they catalyze oxidative folding (27) . This reaction involves the transfer of a disulfide bond from the active site 30 CXXC 33 motif of DsbA to cysteine thiols in newly translocated proteins (28) . Through this disulfide-exchange reaction, the active site cysteines of DsbA become reduced. The enzymatic cycle is completed through oxidation of DsbA by the inner membrane partner
The atomic coordinates and structure factors (codes 4OCE, 4OCF, and 4OD7) have been deposited in the Protein Data Bank (http://wwpdb.org/). 1 Both authors contributed equally to this article. 2 Supported through an Australian Research Council Australian Laureate Fellowship FL0992138 to J. L. M. 3 Supported by an Australian Research Council Future Fellowship FT100100662. 4 protein, DsbB (29) . DsbA from E. coli (EcDsbA) is a highly promiscuous enzyme that catalyzes disulfide bond formation in many cysteine-containing proteins (28) . In contrast, EcDsbB has a very strict binding specificity for EcDsbA (29 (30) . The crystal structure of the complex between EcDsbA and EcDsbB also revealed non-covalent binding of EcDsbB P2 loop residues to the EcDsbA hydrophobic groove (30) . The P2 periplasmic loop sequence of P. mirabilis DsbB (PmDsbB) is identical to that of EcDsbB, suggesting a similar interaction occurs between PmDsbA and PmDsbB.
Here we characterize PmDsbA from P. mirabilis, which shares 59% sequence identity with EcDsbA, and confirm its activity as a DsbA enzyme. We demonstrate that the heptapeptide PWATCDS, derived from the DsbB P2 loop sequence, binds to wild type PmDsbA and to a C30S active site variant (PmDsbAC30S). We report three high-resolution crystal structures including the PmDsbAC30S⅐PWATCDS complex, which represents to our knowledge the first reported example of a peptide bound non-covalently to a DsbA structure. This noncovalent complex provides the critical starting point for the design of non-covalent drugs that act as anti-virulence agents targeting Enterobacteriaceae DsbAs.
EXPERIMENTAL PROCEDURES
Protein Production and Molecular Biology-Codon-optimized wild type P. mirabilis dsbA (GenBank accession number CAR45574), lacking the sequence coding for the predicted signal peptide (amino acids [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , was cloned into a modified pMCSG7 (31) vector using ligation-independent cloning. The cytoplasmic expressed PmDsbA contained an N-terminal His 6 affinity tag followed by a linker region including a tobacco etch virus (TEV) 6 protease cleavage site. The PmDsbAC30S variant was generated from the wild type construct using QuikChange (Agilent Technologies). The following primers were used to introduce the point mutation, forward, GAATTTTTCTCATTTTATTCTCCGCATTGT-TACC and reverse, GGTAACAATGCGGAGAATAAAATG-AGAAAAATTC. Transformed BL21(DE3)pLys cells containing plasmids for either PmDsbA or PmDsbAC30S were grown (1 liter) at 30°C in 2.5-liter baffled shaker flasks for 16 -20 h using autoinduction media (32) . Cells were resuspended in 25 mM Tris, 150 mM NaCl (10 g of cells/100 ml of buffer), and protease inhibitor mixture (diluted 1 in 1000 into the lysate) (BioPioneer Inc., San Diego, CA) and DNase (1300 units/100 ml of lysate) (Roche Applied Science) were added. Lysis was performed in a Cell Disruptor (TS-Series, Constant Systems LTD., UK) applying a single run with a constant pressure of 25 Kpsi. Cell debris was removed by centrifugation (18,500 rpm, 30 min, 4°C, rotor JM-25.5, Beckman Coulter, Brea, CA). The proteins were further purified by immobilized metal ion affinity chromatography using 12 ml/1-liter cells of equilibrated Talon  (Clontech) and eluted with 25 mM Tris, 150 mM NaCl, 200 mM  imidazole after incubation of 30 min at room temperature.  Total protein was determined at 280 nm with a NanoDrop   TM 2000c (Thermo Fisher Scientific). The His 6 affinity tag was removed by TEV cleavage using a 50:1 (w/w) ratio (protein/ TEV-protease) incubated in a 50-ml Falcon tube including 1 mM ␤-mercaptoethanol for 2 h on a rotary mixer at room temperature. After cleavage, the PmDsbA proteins had an additional two non-native residues (Ser Ϫ2 -Asn Ϫ1 ) at the N terminus. To remove imidazole, the mixture was rapidly buffer exchanged into 25 mM Tris, 150 mM NaCl using a Sephadex G-25 fine 16/60 column connected to an ÄKTA system (GE Healthcare). The His 6 -tagged TEV protease was removed by reverse metal ion affinity chromatography using Talon resin (0.5 ml of resin/2 mg of TEV protease) (Clontech, Australia) and the PmDsbA proteins were recovered in the flow through. The final step of purification was performed using a Superdex S75 gel-filtration column (GE Healthcare). Peak fractions were then combined and the protein was oxidized using copper(II)/ 1,10-phenanthroline at 1.7 mM final concentration or reduced using DTT at ϫ25 molar excess. To remove oxidizing or reducing agent, the mixture was then buffer-exchanged into 10 mM HEPES pH 7.4 using a Sephadex G-25 fine 16/60 column. Finally, the protein was concentrated to 100 mg/ml using Amicon Ultra filter devices with a 10-kDa cutoff (Millipore). Yield was generally 120 -150 mg/liter of culture. Protein quality was assessed by SDS-PAGE (NuPAGE system, 4 -12% BisTris gel, Invitrogen, Australia). Molar protein concentrations were determined from calculated extinction coefficients derived from ProtParam (33) .
Purified EcDsbA (GenBank accession number CAA56736) and EcDsbC (GenBank accession number AAA83074), lacking the periplasmic leader signal were expressed and purified as described above for PmDsbA. Yields were generally 120 and 80 mg/liter of culture, respectively. E. coli membrane extracts containing over-expressed EcDsbB (GenBank accession number AAC74269) were prepared as described previously (34) , and resuspended in PBS buffer containing 10% glycerol.
EcDsbA Complementation-E. coli ⌬dsbA (JCB817) and ⌬dsbA/⌬dsbB (JCB818) non-motile strains were used for motility assays as described previously (35) . The gene sequence coding for mature PmDsbA (lacking the periplasmic signal sequence) was cloned into pBAD33 under an arabinose-inducible promoter with an N-terminal EcDsbA signal sequence (36) . As a positive control, EcDsbA was expressed within the same pBAD33 vector background. 2 ϫ 10 6 non-motile E. coli ⌬dsbA (JCB817) and ⌬dsbA/⌬dsbB (JCB818) double-mutant (JCB818) (27) cells harboring pBAD33(EcDsbA) or pBAD33(PmDsbA) were spotted onto the center of a soft M63 minimal agar plate containing 40 mg/ml of each amino acid (except L-cysteine) in the absence or presence of 0.1% arabinose (negative control). Plates were incubated at 37°C and cell motility was monitored after 4 -5 h using a Molecular Imager Gel Doc TM system from Bio-Rad. Complementation experiments were performed as biological triplicates.
Cysteine Thiol Oxidation Assay-A synthetic peptide substrate of EcDsbA (CQQGFDGTQNSCK) with a europium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid group amide coupled to the N terminus and a methylcoumarin amide coupled to the ⑀-amino group of the C-terminal lysine was purchased from AnaSpec (Fremont, CA) and prepared as previously reported (37) .
Assays were performed using a Synergy H1 multimode plate reader (BioTek) as described previously (38) . In brief, fluorescence (excitation ϭ 340 nm and emission ϭ 615 nm) corresponding to disulfide formation in the substrate peptide was measured in a white 384-well plate (PerkinElmer Life Sciences OptiPlate-384, number 6007290) in 50 mM MES, 50 mM NaCl, and 2 mM EDTA at pH 5.5 buffer. The total reaction volume in each well was 50 l, containing 40, 80, or 160 nM PmDsbA or EcDsbA, 1.6 M EcDsbB membrane, and 8 M peptide substrate (added last to initiate the reaction). Controls used were: PmDsbA or EcDsbA ϩ buffer ϩ substrate (no DsbB); EcDsbB ϩ buffer ϩ substrate (no DsbA); buffer ϩ substrate (no DsbA or DsbB); and no components (fluorescence background of the plate, which was subtracted from all other measurements). Three independent experiments (biological replicates) were performed, using three technical replicates for each measurement. The reaction rate was estimated by calculating the increase in fluorescence over the first 8 min of reaction. The fluorescence rates were plotted including the standard deviation calculated from the three biological replicates.
Thermal Stability of PmDsbA-Temperature-induced unfolding of native PmDsbA was recorded by UV circular dichroism as previously reported for other DsbA enzymes (39) using a Jasco J-810 spectropolarimeter (Jasco). The initial redox state of PmDsbA was confirmed by Ellman's assay (40) . The maximum difference in CD signal was determined by subtraction of the CD spectra of the folded protein (25°C) from the unfolded (95°C) protein, for the oxidized and the reduced forms of the protein. Unfolding of oxidized PmDsbA (210 nm) and reduced PmDsbA (213 nm) was monitored in a 1-mm quartz cuvette using a heating rate of 1°C/min from 25 to 95°C. Measurements were carried out using 10 M protein in a buffer containing 100 mM NaH 2 PO 4 /Na 2 HPO 4 , 1 mM EDTA, pH 7.0. To ensure PmDsbA remained reduced throughout the entire measurement, reduced samples contained 0.75 mM DTT. Data were fitted to a two-state unfolding model and errors were calculated using Prism 6 (GraphPad) as described previously (41) .
Redox Properties of PmDsbA-The standard redox potential of PmDsbA was measured utilizing the intrinsic fluorescence of tryptophan residues in PmDsbA, similar to the method used for EcDsbA (42) . In brief, oxidized PmDsbA was equilibrated for 3 h at 25°C in degassed 100 mM NaH 2 PO 4 /Na 2 HPO 4 , pH 7.0, 1 mM EDTA, containing 1 mM oxidized glutathione (GSSG) and a range of reduced glutathione (GSH) concentrations (0 -2000 M). 200 l of PmDsbA from each redox condition was dispensed into a 96-well plate (TPP AG, Switzerland, number 92096) and tryptophan fluorescence was measured (excitation wavelength 280 nm, emission 332 nm) using a Synergy H1 microplate reader and Gen5 2.0 software (Biotek). Data were analyzed in Prism 6 (GraphPad) and the redox potential was calculated as described previously for EcDsbA (42) .
Determination of Cys
30 pK a -Absorbance at 240 nm of the catalytic thiolate anion is pH-dependent allowing the equilibrium between protonated and deprotonated Cys 30 to be measured (43) using a UV-visible spectrophotometer (CARY 50, Agilent Technologies). Absorbance at 240 and 280 nm were measured over pH values starting at 6.5 and decreasing to 2.0, in 0.25 pH unit increments. Samples contained either oxidized or reduced PmDsbA (40 M) in composite buffer (10 mM Tris, 10 mM sodium citrate, 10 mM K 2 HPO 4 , 10 mM KH 2 PO 4 , 200 mM KCl, and 1 mM EDTA) at 22°C. The pK a value was calculated from the fitted curves using the Henderson Hasselbalch equation (pH ϭ pK a Ϫ log ([A 240 /A 280 ] red /[A 240 /A 280 ] ox )). Average and mean Ϯ S.D. from triplicate measurements are plotted.
Disulfide Reductase Activity-DsbA enzymes can reduce the intermolecular disulfide bonds between insulin chains A and B under mild reducing conditions (27) . Disulfide bond reduction of insulin can be followed spectrophotometrically at ϭ 650 nm (A 650 nm ). The A 650 nm value gives a measure of turbidity, which occurs as a result of the increase in production of insoluble B chain of insulin (44) . Samples were prepared in 1-cm cuvettes containing 10 M protein (PmDsbA, EcDsbA, or EcDsbC), 0.33 mM DTT, and 2 mM EDTA in 100 mM NaH 2 PO 4 / Na 2 HPO 4 , pH 7.0. Catalysis was initiated by the addition of 0.131 mM insulin (I0516, Sigma) to the mixture. The assay was repeated three times and the mean Ϯ S.D. of the measurement at each time point was calculated.
Peptide Synthesis-Peptides were synthesized using solidphase peptide synthesis on rink-amide (4-methyl)benzhydrylamine resin (ChemImpex International, Wood Dale, IL) with a loading of 0.65 mmol/g. De-protection of the resin and amino acids was performed using an 80:20 (v/v) mixture of dimethylformamide/piperidine (Rci Labscan, Bangkok Thailand/Auspep, Australia) for 2 ϫ 5 min. L-Amino acids (ChemImpex International) were activated using 4 resin equivalents (eq) and 4 eq of HbtU (O-benzotriazole-N,N,NЈ,NЈ-tetramethyluronium hexafluorophosphate, ChemImpex International) (500 mM) and 5 eq of N,N-diisopropylethylamine (Auspep, Australia) for 5 min before coupling to the de-protected resin for 60 min. After the final coupling, all peptides were acetylated at the N terminus using 4 eq of acetic acid (Chem Supply, Australia), 4 eq of HbtU, and 5 eq of N,N-diisopropylethylamine for 30 min. Cleaving was executed using a 95:2.5:1.25:1.25 (v/v) mixture of trifluoroacetic acid (TFA)/ethanedithiol/triisopropylsilane/ water (H 2 O) (chemicals from Sigma). Cleaved peptides resulted in an amidated C terminus from the resin rink-amide and dried using N 2 gas, washed with diethyl ether (DEE, Ajax Finechem, Sydney Australia), and dissolved in a 80:20 (v/v) mixture of acetonitrile/H 2 O (RCI Labscan, Bangkok, Thailand) before purification on HPLC. Purification was executed on a C 18 column (Phenomenex, Torrance CA) using a gradient from 20 to 80% of acetonitrile and TFA 0.1%. Fractions were analyzed by mass spectrometry (Waters Micromass LCT, Milford, CT) and the purified peptide was lyophilized using a freeze drier (Christ, Osterode am Harz, Germany).
Peptide-induced Thermal Shift Measurements-25 M PmDsbA in phosphate-buffered saline (PBS), pH 7.4, was incubated with peptide PWATCDS at concentrations ranging from 125 M to 4 mM for 1 h. Then Sypro Orange (S-6650, Invitro-gen) was added to a 5ϫ final concentration (stock concentration ϫ5000). Controls contained either no peptide, no DsbA, or the dye alone. Measurements were conducted in a white 384-well plate (Perkin Elmer OptiPlate-384, number 6007290) with 5 replicates. Fluorescence emission from Sypro Orange binding to unfolded protein was measured following a temperature time course increasing from 25 to 95°C (heat rate ϭ 0.05°C/s) using a VIAA7 Real-time PCR system (Invitrogen) with a ϭ 585 Ϯ 15 nm wavelength filter. Raw data were analyzed using Prism 6 (GraphPad). Fluorescence emission was fitted to a classic Boltzmann sigmoidal curve, and the inflection point was used as the melting temperature, T m . To determine ⌬T m (the shift in melting temperature in the presence of peptide), the T m value for the wild type protein was subtracted from the T m value for PmDsbA-PWATCDS and the T m value for the variant PmDsbAC30S was subtracted from the T m value for PmDsbAC30S-PWATCDS. ⌬T m values are presented as the mean Ϯ S.D. from 5 replicates. A significant ⌬T m is considered to be greater than two times the S.D. of the T m value for the protein in the absence of ligand (45) .
Isothermal Titration Calorimetry-Evaluation of affinity and thermodynamics of binding between PWATCDS and PmDsbA or PmDsbAC30S were assessed by isothermal titration calorimetry (ITC) using an Auto-iTC 200 instrument (MicroCal TM , GE Healthcare). The sample cell was loaded with 200 l of purified protein (oxidized PmDsbA or untreated PmDsbAC30S) at 100 M concentration in 25 mM HEPES, pH 7.4, 50 mM NaCl, 0.8% dimethyl sulfoxide (ITC buffer). The syringe was filled with purified peptide PWATCDS in ITC buffer at a concentration of 4 mM. Titrations were conducted at 25°C using 19 consecutive injections of 2 l each delayed by 180 s with a stirring speed of 1000 rpm. In every experiment an initial 0.5 l of peptide was injected to avoid slow leakage of titrant and this data point was discarded for binding analysis. As a control for background noise, titration of PWATCDS into a solution containing ITC buffer only was performed. The association constant (K a ϭ 1/K d ), free energy (⌬G), and enthalpy change (⌬H) were calculated by fitting the data to a single-site binding model using the MicroCal Origin software (Origin 7.0 SR4 version 7.0552␤) and correcting peptide concentrations to adjust the stoichiometry parameter close to 1.0. Entropy change (⌬S) was deduced from the standard free energy equation ⌬G ϭ ⌬H Ϫ T⌬S. Parameters reported include the mean Ϯ S.D. across three replicates. The calculated c-value for these measurements is 12.
Crystallization, Structure Determination, and Structural Analysis-Crystallization screening was performed at the University of Queensland ROCX diffraction facility. Protein crystallization trials were performed in 96-well plates using the hanging drop vapor diffusion method at 8 or 20°C. In general, purified protein (200 nl) was mixed with crystallization solution (200 nl) using a Mosquito crystallization robot (TTP Labtech, UK), and trays were incubated and imaged in a RockImager 1000 (Formulatrix). Wild type PmDsbA was crystallized by mixing a 1:3.3 molar ratio of the protein⅐peptide complex PmDsbA⅐PSPWATCDF (3 mM protein, 10 mM peptide, 2% dimethyl sulfoxide incubated on ice for 1 h) with 0.5 l of 15% PEG 3350 and 0.4 M sodium malonate, pH 5.0, and incubating the drop over the same solution at 20°C. The presence of the peptide permitted crystallization but no density was evident for the peptide in the phased data; the final refined structure from this condition is referred to as native PmDsbA. Crystals were harvested in cryo solution (25% PEG 3350, 0.4 M sodium malonate, pH 5.0, 20% PEG 400) and immediately flash frozen in liquid nitrogen.
PmDsbAC30S crystals appeared overnight at 8°C in 0.2 M KSCN, 23% PEG 3350 using a 1:10 molar ratio of the protein⅐peptide complex (1.5 mM protein and 15 mM PWATCDS, final concentrations of both, incubated on ice for 1 h); again the presence of the peptide permitted crystallization but there was no evidence of peptide binding in the electron density maps. The cryo solution used was 0.2 M KSCN, 25% PEG 3350, and 20% PEG 400. The structure of the protein derived from this condition is referred to as PmDsbAC30S.
PmDsbAC30S⅐PWATCDS co-crystals grew at 20°C using a 1:10 molar ratio of the protein⅐peptide complex (3 mM protein, 30 mM peptide, final concentrations of both), with the two components incubated on ice for 1 h prior to crystallization. The protein⅐peptide solution was then mixed with an equal volume of crystallization solution, which contained 0.2 M KSCN, 22% PEG 3350, 0.2 M non-detergent sulfobetaine (NDSB-221). Differences in crystallization conditions in comparison to the PmDsbAC30S crystals that did not yield bound peptide included higher concentrations of protein and peptide (but the same molar ratio), the use of NDSB-221 as an additive and an incubation temperature of 20°C (rather than 8°C). Crystals were flash frozen in cryo solution consisting of 0.3 M KSCN, 30% PEG 3350, and 20% PEG 400.
Diffraction data for all three crystal structures were measured at the Australian Synchrotron MX2 beamline at a wavelength of 0.9537 Å, and recorded with an ADSC Quantum 315r detector controlled by BLU-ICE (46) . Reflections were indexed and integrated in Mosflm (47) or XDS (48), analyzed in Pointless (49) , and scaled in SCALA (49) from the CCP4 suite (50) . Phases for PmDsbA were obtained by molecular replacement using PHASER (51) with EcDsbA as a template (PDB code 1FVK, sequence identity 59%). PmDsbAC30S⅐PWATCDS were solved using the wild type PmDsbA structure as the template. Initial electron density maps from PHASER were improved by cycles of iterative refitting of the model using the program COOT (52) and PHENIX.refine (53) . The refinement of the complex structure was stalled at R-factor/R-free: 30/33%. Phenix.xtriage analysis indicated that the diffraction data were twinned with a twinning fraction of 0.49. The twin target function implemented in PHENIX was applied in further refinement cycles with the twinning operator Ϫhϩk, k, Ϫl. The final R-factor/R-free was 17.2/19.9%. For PmDsbAC30S⅐ PWATCDS, the density corresponding to the bound peptide was modeled for all seven residues including N-terminal acetylation and C-terminal amidation. In addition, a malonate anion was modeled into the crystal structure of PmDsbA and four SCN molecules were modeled into the PmDsbAC30S⅐ PWATCDS crystal structure with one pair in each protomers A and C. One thiocyanate molecule is buried between ␣1 and ␤2 of protomers A/C, whereas the second molecule binds between Pro and PmDsbAC30S helix ␣1, possibly forming a weak hydrogen bond with the Pro backbone carbonyl (distance N:O ϭ 3.4 Å). Thiocyanate molecules do not appear to influence peptide binding, because the peptide binding site and conformation is identical in protomer B, which lacks a bound thiocyanate.
Data processing and refinement statistics for all three crystal structures are provided in Table 1 . Molecular figures were generated using PyMOL (The PyMOL Molecular Graphics System, version 1.6.0.0 Schrödinger, LLC) and figures of the electrostatic potential were generated using APBS (54). r.m.s. deviation calculations and structural alignments were conducted in PyMOL and FATCAT (55) . Interaction analyses were conducted with the program COOT (52) and the PDBePISA (56) and Cocomaps servers (57) .
RESULTS

PmDsbA Catalyzes Disulfide Formation in Vitro and in Vivo-
DsbA enzymes catalyze oxidative folding, or the introduction of disulfide bonds into proteins. To assess whether PmDsbA has dithiol oxidase activity we assessed its activity in an in vitro peptide oxidation assay. A europium-labeled peptide (CQQGFDGTQN-SCK) fluoresces when the two cysteines are oxidized, but not when the cysteines are reduced (37) . We found that PmDsbA, like EcDsbA, catalyzed peptide thiol oxidation as evident by an increase in the fluorescent signal over time (Fig. 1A) . The fluorescence rate increased with increasing concentrations of PmDsbA and EcDsbA (Fig. 1A) . PmDsbA catalysis was a little slower than that of EcDsbA at the same enzyme concentrations. This slightly reduced activity may reflect the use of a peptide derived from an EcDsbA substrate. Nonetheless, the results establish that PmDsbA catalyzes dithiol oxidation in a model substrate.
We also assessed the ability of PmDsbA to complement EcDsbA in vivo. E. coli strains deficient in the P-ring protein FlgI fail to assemble functional flagella (58) . Moreover, E. coli strains lacking EcDsbA, EcDsbB, or both, have the same phenotype (59) because FlgI requires a disulfide bond to function. The non-motile strains E. coli ⌬dsbA (JCB817) and ⌬dsbA/⌬dsbB (JCB818) were therefore used for in vivo DsbA complementation experiments. When EcDsbA or PmDsbA were expressed in JCB817 following arabinose induction, full rescue of motility was observed in JCB817 (Fig. 1B) . However cells from the double knock-out (JCB818) remained non-motile for both PmDsbA and EcDsbA. These results demonstrate that PmDsbA can replace EcDsbA functionally in vivo in the context of flagella assembly. Because EcDsbB was also essential for complementation in this experiment, the results confirm that PmDsbA and EcDsbB can form a functionally competent system. This was expected because the P2 loop sequence from PmDsbB is identical to that of EcDsbB. Furthermore, the P. mirabilis FlgI homologue shares 74% sequence identity with EcFlgI including two conserved cysteine residues.
PmDsbA Shares the Same Characteristic Redox Properties as EcDsbA-DsbA enzymes exhibit unique properties that contribute to their ability to catalyze disulfide bond formation (28, 60). We next established whether these characteristics are shared by PmDsbA. First, we investigated the relative thermostability of the oxidized and reduced forms of the enzyme. In most DsbAs, the reduced form of the CXXC active site is more stable than the oxidized form. For instance, the melting temperature of reduced EcDsbA is almost 10 K higher than that of the oxidized form (39) . Similarly, we found that reduced PmDsbA (T m red 348.4 Ϯ 0.1 K) is 10 K more stable than oxidized PmDsbA (T m ox 338.4 Ϯ 0.2 K) (Fig. 1C) . DsbAs are also highly oxidizing. The redox potential of EcDsbA is Ϫ122 mV (42) and the range of values reported for other DsbAs varies from Ϫ80 mV for NmDsbA1 (37) to Ϫ163 mV for WpDsbA (41) . Nevertheless, closely related (Ͼ80% sequence identity) homologues of EcDsbA such as SeDsbA and KpDsbA have redox potential values very similar to that of EcDsbA (Ϫ126 and Ϫ116 mV, respectively). We determined the redox potential of PmDsbA to be Ϫ129 mV (Fig. 1D) , which is consistent with those of other Enterobacteriaceae DsbAs.
The oxidizing nature of DsbA proteins is thought to be a consequence of the highly acidic cysteine in the CXXC active site motif. The pK a of 3.3 for this nucleophilic cysteine Cys 30 for EcDsbA is unusually low for a cysteine (pK a 9.0) (61) . Values reported for other DsbAs vary from 3.0 (NmDsbA1) (62) to 5.1 (VcDsbA) (63) . We measured the pK a of the equivalent cysteine in PmDsbA, by pH-dependent specific absorbance at ϭ 240 nm, and determined the value to be 4.0 (Fig. 1E) . Thus, the nucleophilic . D, measurement of PmDsbA redox potential. PmDsbA was equilibrated in glutathione (GSSG/GSH) redox buffers to measure the equilibrium constant K eq (187. 5 Ϯ 6 M), which corresponds to a redox potential of Ϫ129 mV. E, absorbance of the catalytic thiolate anion is pH-dependent and this property was used to determine that the pK a of PmDsbA Cys 30 is 4.0. F, disulfide reductase activity measured by following A 650 nm. PmDsbA has activity similar to that of EcDsbA, and much lower than that of the isomerase EcDsbC. For panels A and C-F, data are presented as mean Ϯ S.D. from three biological replicates. The error bars for the DsbA-only and buffer-only controls in panel A are essentially 0 as there was no increase in fluorescence over the period of the experiment.
cysteine of PmDsbA, like that of other DsbAs, is likely to be in the thiolate form at physiological pH when the enzyme is reduced.
Although DsbA proteins are dithiol oxidases they can catalyze disulfide reduction in the presence of mild reducing agents such as DTT. Typically, insulin is used as a substrate to study in vitro disulfide bond reduction. The two chains of insulin are linked by three disulfide bonds, which can be rapidly reduced by disulfide reductases such as the disulfide isomerase EcDsbC. This reduction leads to separation of the insulin A and B chains, and precipitation of the insoluble B chain. Reduction can be followed by measuring the increase in turbidity of the solution over time. We found that PmDsbA is able to reduce the disulfide bonds of insulin as rapidly as EcDsbA (Fig. 1F) , but more slowly than the specialist reductant EcDsbC. In summary, the redox properties of PmDsbA reported here place it in the same class as EcDsbA and other Enterobacteriaceae DsbAs such as S. enterica DsbA (SeDsbA) and K. pneumoniae DsbA (KpDsbA) (18) .
PWATCDS Binding to PmDsbA and PmDsbAC30S-We were interested to understand how peptides interact with PmDsbA, as the basis for future peptidomimetic inhibitor development. The low resolution crystal structures and NMR characterization of the EcDsbB⅐EcDsbA complex revealed that the EcDsbB periplasmic loop P2 forms a mixed disulfide with the nucleophilic cysteine of EcDsbA and binds to a hydrophobic groove near the active site (29, 30, 64, 65) . The peptide sequence of the EcDsbB P2 loop 98 PSPFATCDF 106 is conserved in PmDsbB ( 99 PSPFATCDF 107 ) suggesting that a similar interaction occurs between PmDsbA and PmDsbB. From the sequence of this P2 loop peptide, we developed a shorter, modified peptide PWATCDS optimized for solubility, binding affinity, and inhibition of EcDsbA. 7 Briefly, alanine scanning, peptide length scouting, and substitution of specific residues showed that the peptide PWATCDS had a good affinity to mass ratio for binding to EcDsbA. We hypothesized that this peptide would also interact with PmDsbA, and therefore evaluated its binding using thermal shift assay and ITC.
T m values for PmDsbA and PmDsbAC30S (a variant in which the nucleophilic cysteine was replaced by serine) were measured in the presence and absence of the peptide PWATCDS, with varying peptide concentrations. For PmDsbA, T m values of ϩ2.0, ϩ4.1, and ϩ5.0 K were observed at peptide concentrations of 1, 2, and 4 mM, respectively, suggesting that PWATCDS binds to PmDsbA. These data show that the T m shift continued with increasing peptide concentration beyond saturation, as is commonly observed in this assay (66) . When the variant PmDsbAC30S was used, thermal shifts (⌬T m Ͼ ϩ0.3 K) were detectable at concentrations of PWATCDS ranging from 250 M to 4 mM. However, the maximum ⌬T m at 4 mM was significantly lower than that at the same concentration for PmDsbA (⌬T m ϩ1.5 K, compared with 5.0 K, respectively) ( Fig. 2A) . This difference in ⌬T m suggests the possibility of different binding modes.
We also investigated the interaction using ITC. An exothermic reaction was observed when titrating PWATCDS into PmDsbA (Fig. 2B) . Analysis of the raw data using a 1:1 binding model revealed a binding affinity K D of 8.3 Ϯ 0.4 M with a high enthalpic contribution (⌬H ϭ Ϫ13.7 Ϯ 0.3 kcal/mol) and an unfavorable entropy of binding (⌬S ϭ Ϫ22.3 Ϯ 1.1 cal/mol/ deg). When PmDsbAC30S was used, there was no evidence of PWATCDS binding by ITC under these same conditions (Fig.  2C) . Clearly, the C30S mutation reduced the affinity of peptide binding, as evidenced by both thermal shift and ITC. Nevertheless, we were able to generate a crystal structure of this complex as described below. These differing outcomes for the apparently weak complex of PmDsbAC30S⅐PWATCDS may be a consequence of different experimental design (thermal shift and crystallization used a 1-h preincubation of peptide with PmDsbAC30S, ITC methodology does not allow this; ITC was performed at 25°C, whereas preincubation was done at 4°C and crystallization at 20°C) or different experimental conditions (buffer, pH, and concentration of peptide as outlined under "Experimental Procedures").
Crystal Structure of PmDsbA-To investigate the different binding modes further, we attempted to determine the crystal structures of PmDsbA and PmDsbAC30S, in the presence of the peptide PWATCDS. We were unable to generate a crystal of a stable complex of PmDsbA with PWATCDS. However, crystals of PmDsbA and PmDsbAC30S without peptide, and PmDsbAC30S with peptide yielded high-resolution diffraction data (PmDsbA, 1.77-Å resolution; PmDsbAC30S, 1.98-Å resolution; and PmDsbAC30S-PWATCDS, 1.6-Å resolution).
PmDsbA crystallized in a tetragonal crystal system and was solved (PDB code 4OCE) by molecular replacement using the EcDsbA structure (PDB code 1FVK) as a template. One protein chain is present in the asymmetric unit, and this has a typical DsbA-like architecture, comprising a TRX core domain (␤1, ␤2, ␣1, ␤3, C-terminal region of ␣6, ␤4, ␤5, and ␣7), interrupted by an ␣-helical domain (␣2-␣5 and the N-terminal region of ␣6). This PmDsbA structure is structurally similar to other Enterobacteriaciae DsbAs including EcDsbA (PDB code 1FVK (67)), KpDsbA (PDB code 4MCU (18)), and SeDsbA (PDB code 3L9S (68)) (Fig. 3A) . This is reflected in the r.m.s. deviation of 1.0 -1.2 Å comparing 177 C␣ atoms from equivalent positions of these enzymes. Fig. 3B shows a structure-based sequence alignment of PmDsbA with homologous DsbA proteins from clinically relevant pathogens that share Ͼ59% sequence identity. Sequences are highly conserved, especially at the active site CPHC motif. Sequence identity translates into overall structural similarity between DsbA proteins from these pathogens.
The sequence and structure of the active site motif (CPHC) and the cis-Pro loop are identical in these DsbA homologues. However, helix ␣1 and the loops connecting ␤1 and ␤2, and ␣3 and ␣4 differ in their relative positions. Most importantly loop L3 that connects ␤3 and helix ␣7 varies across the structures. The EcDsbA L3 residues Asp 167 , Thr 168 , and Ser 169 are positioned closer to the active site helix ␣1 than the equivalent residues (Ala 167 , Lys 168 , and Ser 169 ) in PmDsbA. This region is relatively hydrophobic in both PmDsbA and EcDsbA, although more basic in PmDsbA than in EcDsbA due to the presence of Lys 159 in the former and Gln 160 in the latter. Overall these differences in structure are relatively minor compared with the structures of other DsbA proteins, such as Pseudomonas aeruginosa DsbA (25% identity with PmDsbA, r.m.s. deviation 2.2 Å, 175 C␣, PDB code 3H93 (35)), and Wolbachia pipientis DsbA1 (16% identity with PmDsbA, r.m.s. deviation 3.6 Å, 151 C␣, PDB code 3F4R (41)).
Crystal Structure Determination of PmDsbAC30S and PmDsbAC30S⅐PWATCDS-We solved the structure of the active site mutant PmDsbAC30S (PDB code 4OCF). The crystals grew in the presence of peptide, but no bound peptide was evident in the electron density map. We therefore used this structure of PmDsbAC30S to assess whether replacement of Cys 30 with Ser 30 induced any structural changes. The mutant crystallized in a monoclinic crystal system containing 4 protomers in the asymmetric unit. The structure was solved by molecular replacement using the coordinates of PmDsbA described above. The average r.m.s. deviation for comparison of the 6 combinations of the 4 protomers range from 0.3 to 0.7 Å for 177 equivalent C␣ atoms (residues 6 -181).
PmDsbAC30S in complex with peptide PWATCDS crystallized in a trigonal crystal system, containing 3 protomers in the asymmetric unit. The complex was solved by molecular replacement using PmDsbA (PDB code 4OD7) as the template. All three protomers (A, B, and C) reveal strong electron density corresponding to bound PWATCDS. The average r.m.s. deviation for the 3 comparisons of the protomers in this crystal structure range from 0.4 to 0.6 Å for 177 equivalent C␣ atoms (residues 6 -181 30 and Cys 33 in the native PmDsbA structure were modeled as a mixture of oxidized and reduced (ratio 0.7:0.3). In the oxidized state the two sulfurs (Fig. 3C ) are 2.2 Å apart, reflecting the typical length of a covalent disulfide bond found in other oxidized DsbA structures (e.g. EcDsbA and SeDsbA, S-S distance 2.0 Å) (26, 68) . The dithiol form of the cysteines is likely a consequence of radiationinduced disulfide reduction. The distance between the dithiol sulfurs is 3.4 Å. In the PmDsbAC30S and PmDsbAC30S⅐PWATCDS structures, the distance between the hydroxyl oxygen of Ser 30 and the sulfur atom of Cys 33 varies between 3.3 and 3.5 Å (Fig.  3D) . These distances are in agreement with those of other reduced DsbA structures (e.g. KpDsbA 3.3-3.8 Å) (18) . Overall, there is no apparent change in the active site upon binding of the peptide.
Peptide Binding Mode and Interaction with PmDsbAC30S-The binding mode of the peptide (Fig. 4, A and B) is highly conserved across the three protomers (r.m.s. deviation 0.1-0.2 Å over all 82 atoms). The electron density from this high-resolution structure provides strong evidence for both the position and conformation of the bound peptide (Fig. 4C) . The binding site for PWATCDS (residues 1 to 7) includes the hydrophobic groove and the active site regions (CXXC and cis-Pro motif) of the enzyme. As expected, the hydrophobic residues Pro 1 and Trp 2 (italics indicate peptide residues) interact with the hydrophobic groove, and the C-terminal residues interact with the cis-Pro region of the active site.
However, the observed binding mode was not entirely as predicted. On the basis of the EcDsbA⅐EcDsbB covalent complex, Non-covalent Interaction between Peptide and DsbA Active Site JULY 11, 2014 • VOLUME 289 • NUMBER 28 (Fig. 4D) .
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Comparison of Peptide Binding Mode with DsbA-DsbB Complexes-The EcDsbB P2 loop (sequence PSPFATCDF) and the synthetic peptide we used (PWATCDS) share the same binding location on EcDsbA and PmDsbAC30S, respectively. The EcDsbA-EcDsbB complex (3.7-Å resolution (30) (Fig. 4, E and F) .
The r.m.s. deviation for comparison of PWATCDS with the EcDsbB P2 loop conformation is relatively high (2.2 Å for 28 backbone atoms), because of the bulge in the peptide confor- 
DISCUSSION
The increasing incidence of infections caused by multidrugresistant pathogens represents a serious global human health issue. Indeed, the emergence of carbapenem-resistant Enterobacteriaceae threatens to make common infections such as urinary tract infections untreatable (69) . Antibiotic resistance is spreading rapidly and treatment options are becoming increasingly limited. One possible approach to address the paucity of new antimicrobials in the developmental pipeline lies in the generation of novel anti-virulence drugs (19, 70) .
The Gram-negative DsbA/B system has been proposed as a target for the development of novel anti-virulence drugs (17) . Targeting DsbA/B for development of inhibitors could be beneficial in many ways. First, DsbA is not essential for bacterial survival (27) although it plays an essential role in virulence (17) . Thus, inhibiting DsbA/B would not kill bacteria and this property may reduce the selective pressure to develop resistance. Second, structures of several DsbA homologues have been solved (18, 28, 71) , providing a framework for structure-based drug design. Third, DsbA structures and properties are more highly conserved than the structures and sequences of virulence factors across pathogens (18) . Therefore, inhibitors that target one DsbA enzyme within a subclass are likely to block DsbAs within the subclass offering the possibility of mediumspectrum inhibitors (18) .
Designing an inhibitor to block a protein-protein interface, such as that of a DsbA, requires a comprehensive knowledge of its binding interactions. Here we have used an innovative approach to define the interaction surface of PmDsbA by using knowledge from the low resolution crystal structure of EcDsbA-EcDsbB. We characterized a peptide derived from the sequence of DsbB, showed that it bound to PmDsbA and cocrystallized it in a non-covalent complex with PmDsbAC30S. This provides the first example of a high-resolution crystal structure of a DsbA in complex with a non-covalently bound peptide. Two previously published structures of DsbA in complex with bound peptides include (i) EcDsbA bound covalently with a substrate SigA-derived peptide; and (ii) Xyfella fastidiosa DsbA also bound covalently with a peptide that co-crystallized fortuitously.
P. mirabilis associated infections are often difficult to treat due to its propensity to form biofilms (4) . Two cell surface organelles associated with P. mirabilis biofilm formation, mannose-resistant Proteus-like (MR/P) fimbriae (72) and flagella (which mediate swarming) (4), require DsbA for their correct assembly. Taken together, our data show that PmDsbA exhibits redox, functional, and structural properties typical of the DsbA class Ia enzymes (73) , which extends to all DsbAs characterized to date from Enterobacteriaceae (18) . We expect that the structural details of the peptide binding mode and the interactions observed will likely hold true for all of these enzymes. Specifically, the hydrophobic groove and the cis-Pro loop provide key points of interaction that could be exploited further. The highresolution crystal structure of the non-covalent complex between PmDsbAC30S and peptide may provide an important platform for the development of peptidomimetic antivirulence compounds targeting PmDsbA and by extension the DsbAs from all Enterobacteriaceae.
